Astrazeneca plc - ADR logo

AZN

Astrazeneca plc - ADR

$66.29

Earnings Summary

Revenue
$10771Mn
Net Profits
$360Mn
Net Profit Margins
3.34%

Highlights

Revenue:

Astrazeneca plc - ADR’s revenue jumped 31.03% since last year same period to $10771Mn in the Q2 2022. On a quarterly growth basis, Astrazeneca plc - ADR has generated -5.43% fall in its revenue since last 3-months.

Net Profits:

Astrazeneca plc - ADR’s net profit fell -34.55% since last year same period to $360Mn in the Q2 2022. On a quarterly growth basis, Astrazeneca plc - ADR has generated -6.74% fall in its net profits since last 3-months.

Net Profit Margins:

Astrazeneca plc - ADR’s net profit margin fell -50.05% since last year same period to 3.34% in the Q2 2022. On a quarterly growth basis, Astrazeneca plc - ADR has generated -1.38% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Astrazeneca plc - ADR post its latest quarter earnings

EPS Estimate Current Quarter
0.77
EPS Estimate Current Year
0.77

Highlights

EPS Estimate Current Quarter:

Astrazeneca plc - ADR’s earning per share (EPS) estimates for the current quarter stand at 0.77 - a -7.23% fall from last quarter’s estimates.

EPS Estimate Current Year:

Astrazeneca plc - ADR’s earning per share (EPS) estimates for the current year stand at 0.77.

Key Ratios

Key ratios of the Astrazeneca plc - ADR post its Q2 2022 earnings

Earning Per Share (EPS)
0.86
Return on Assets (ROA)
0.06
Return on Equity (ROE)
-0.05
Dividend Per Share (DPS)
2.9

Highlights

Earning Per Share (EPS):

Astrazeneca plc - ADR’s earning per share (EPS) jumped 91.11% since last year same period to 0.86 in the Q2 2022. This indicates that the Astrazeneca plc - ADR has generated 91.11% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Astrazeneca plc - ADR’s return on assets (ROA) stands at 0.06.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Astrazeneca plc - ADR’s return on equity (ROE) stands at -0.05.

Dividend Per Share (DPS):

Astrazeneca plc - ADR declared 2.9 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-03-31
0.83
0.95
14.46%

Company Information

AstraZeneca plc is an English pharmaceutical company located in Cambridge. It is a multinational pharmaceutical and biotechnology firm based in the United Kingdom and Sweden. The company operates in over 100 countries and caters to the requirements of millions of people globally. Among the significant ailments covered by the company's product range are oncology, gastrointestinal, infectious, respiratory, and inflammatory disorders. Astra AB and Zeneca Group Plc amalgamated to establish AstraZeneca in 1999. Astra AB was founded in 1913 by 400 Swedish doctors. Zeneca Group PLC was created in 1993 when the British chemicals business ICI (formed by the amalgamation of four British chemical companies) demerged its medicines, agrochemicals, and specialist divisions to become Zeneca Group PLC. The merger is one of the world's largest pharmaceutical businesses, having purchased several corporations, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013), and Definiens (by MedImmune in 2014). The organisation undertakes research and development in three strategic locations: England, Sweden, and Maryland, United States. The Oxford–AstraZeneca vaccine was approved for use in India in January 2021, paving the way for a large-scale vaccination campaign in the world's second-most populous country. The Serum Institute of India later stated that the Oxford–AstraZeneca shot would be manufactured locally under the brand name COVISHIELD. Currently Astrazeneca plc - ADR has a market cap of $200.56 Billion. It has a P.E ratio of -175.63. The shares of Astrazeneca plc - ADR are trading at $62.7. .

Organisation
Astrazeneca plc - ADR
Headquarters
Cambridge, Cambridgeshire, United Kingdom
Employees
76.1K
Industry
Health Technology
CEO
Pascal Soriot